U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07756242) titled 'Pharmacokinetic Study of Therapeutic Plasma Exchange' on May 12.
Brief Summary: The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.
Study Start Date: Nov., 2026
Study Type: OBSERVATIONAL
Condition:
Immune-related Adverse Event
Intervention:
DEVICE: Spectra Optia Apheresis System
Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Chicago
Published by HT Digital Content Services with permission from Health Daily...